

Table 2 Surgical management and pathological features

		Number (%)
Breast surgery	Breast conserving surgery	1242/4976 (25)
	Modified radical mastectomy	3593/4976 (72.2)
	Not recorded	141/4976 (2.8)
Axillary surgery	No axillary dissection	31/4976 (0.6)
	Sentinel lymph node dissection	163/4976 (3.3)
	Axillary lymph node dissection	4782/4976 (96.1)
Staging (n = 4566)	Stage 0	39/4566 (0.8)
	Stage I	556/4566 (12.3)
	Stage II	1923/4566 (42.1)
	Stage III	1717/4566 (37.6)
	Stage IV	331/4566 (7.2)
Histological type (n = 4459)	Intraductal carcinoma	3960/4459 (88.8)
	Invasive lobular carcinoma	222/4459 (5.0)
	Mixed	116/4459 (2.6)
	Others	161/4459 (3.6)
Grade (n = 4107)	I	104/4107 (2.5)
	II	3425/4107 (83.4)
	III	578/4107 (14.1)
Presence of LVI (n = 3533)		2829/3533 (80.0)
ECE (n = 3666)		1657/3666 (45.2)
ER (n = 4550)	Negative	681/4550 (15.0)
	Positive	3869/4550 (85.0)
PR (n = 4550)	Negative	1005/4550 (22.0)
	Positive	3545/4550 (78.0)
HER2 status (n = 3066)	Negative	2605/3066 (86.7)
	Positive	461/3066 (15.3)
Ki67 (n = 775)	Low (<14)	217 (28.0)
	Moderate (≥14 - 20)	79 (10.0)
	High (≥20)	479 (61.8)

ECE = extracapsular extension; ER = estrogen receptor; LVI = lymphovascular invasion; PR = progesterone receptor.